Deanna Stopperich, NP
Family · Jamestown, INNPI 1902076284
Payments from drug & device makers
Across 322 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$937
- Lilly USA, LLC$771
- Amgen$546
- GSK$428
- AstraZeneca$405
- Novo Nordisk$371
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,139100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 74 | $937 |
| Lilly USA, LLC | 48 | $771 |
| Amgen | 31 | $546 |
| GSK | 26 | $428 |
| AstraZeneca | 21 | $405 |
| Novo Nordisk | 23 | $371 |
| Otsuka America Pharmaceutical, Inc. | 14 | $249 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $246 |
| Pfizer | 9 | $150 |
| Bayer | 6 | $138 |
| Lundbeck LLC | 7 | $121 |
| Exact Sciences | 5 | $96 |
| Endo USA, Inc. | 5 | $79 |
| Sanofi-aventis U.S. LLC | 5 | $71 |
| Dexcom, Inc. | 3 | $69 |
| Astellas Pharma US Inc | 2 | $65 |
| Idorsia Pharmaceuticals US Inc | 4 | $61 |
| Novartis | 3 | $40 |
| Inspire Medical Systems, Inc. | 2 | $39 |
| Mylan Specialty L.p. | 2 | $36 |
| Boehringer Ingelheim | 2 | $33 |
| Nestle Healthcare Nutrition Inc. | 2 | $31 |
| Endo Pharmaceuticals Inc. | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 1 | $28 |
| Alkermes, Inc. | 1 | $20 |
| Merck | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
How this compares
$5,139 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 141 | $162,040 |
| EliquisApixaban | 85 | $82,508 |
| JardianceEmpagliflozin | 73 | $68,945 |
| RybelsusSemaglutide | 51 | $63,438 |
| RexultiBrexpiprazole | 22 | $36,751 |
| OzempicSemaglutide | 27 | $27,698 |
| VraylarCariprazine Hcl | 17 | $27,592 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $24,962 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $21,011 |
| MyrbetriqMirabegron | 29 | $19,445 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $18,367 |
| LinzessLinaclotide | 21 | $16,945 |
| Repatha SureclickEvolocumab | 18 | $15,764 |
| TradjentaLinagliptin | 12 | $12,850 |
| XareltoRivaroxaban | 13 | $12,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $771 | $162,040141 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $33 | $100,983124 claims |
| Novo NordiskRybelsus, Ozempic | $371 | $91,13678 claims |
| PfizerEliquis | $150 | $82,50885 claims |
| AbbVieVraylar, Linzess | $937 | $44,53738 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $249 | $36,75122 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $428 | $27,44243 claims |
| AstraZenecaBreztri Aerosphere | $405 | $24,96236 claims |
| Astellas Pharma US IncMyrbetriq | $65 | $19,44529 claims |
| NovartisEntresto | $40 | $8,39911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Jamestown
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.